Top News
Latest News
INVESTMENT
6 Apr 2026
RNA Gets a $2.4B Promotion at Eli LillyPARTNERSHIPS
31 Mar 2026
RNA Meets Cell Therapy, and Texas Is Holding the HandshakeREGULATORY
26 Mar 2026
No Trial? No Problem. FDA Rewrites the RNA RulesINVESTMENT
23 Mar 2026
New Funding Backs Precision in mRNA Medicine
Fatty Bubbles and the $2.25 Billion Peace
PARTNERSHIPS
17 Mar 2026
Moderna settles landmark LNP patent dispute for up to $2.25B, securing a royalty-free delivery license for its infectious disease vaccine programs
INVESTMENT
6 Apr 2026
RNA Gets a $2.4B Promotion at Eli Lilly
Eli Lilly acquires Orna Therapeutics for up to $2.4B, bringing circular RNA and in vivo CAR-T into its US pipeline
PARTNERSHIPS
31 Mar 2026
RNA Meets Cell Therapy, and Texas Is Holding the Handshake
Cellipont and Soter Bio launch an integrated US platform linking GMP RNA production to cell therapy manufacturing
REGULATORY
26 Mar 2026
No Trial? No Problem. FDA Rewrites the RNA Rules
FDA's Plausible Mechanism Framework opens a structured US approval route for RNA-based therapies targeting ultra-rare genetic diseases
INVESTMENT
23 Mar 2026
New Funding Backs Precision in mRNA Medicine
BreezeBio raises $60M to push precision mRNA delivery into the clinic, targeting diabetes and cancer with its NanoGalaxy platform
PARTNERSHIPS
17 Mar 2026
Fatty Bubbles and the $2.25 Billion Peace
Moderna settles landmark LNP patent dispute for up to $2.25B, securing a royalty-free delivery license for its infectious disease vaccine ...
REGULATORY
12 Mar 2026
Moderna's Flu Vaccine Clears a Regulatory Hurdle
A swift FDA reversal puts Moderna's mRNA flu shot back on track and sharpens the regulatory playbook for RNA developers
SUBSCRIBE FOR UPDATES
By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.